Roche Pegasys/Copegus Monitoring For Severe Infections Advised By Cmte.
Executive Summary
Hepatitis C patients receiving Roche's Pegasys/ Copegus should be actively monitored for hematologic abnormalities and infections, FDA's Antiviral Drugs Advisory Committee recommended Nov. 14
You may also be interested in...
Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says
Treatment with Roche's Pegasys/Copegus should be dosed according to hepatitis C virus genotype in order to optimize the product's risk/benefit ratio, FDA's Antiviral Drugs Advisory Committee recommended
Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says
Treatment with Roche's Pegasys/Copegus should be dosed according to hepatitis C virus genotype in order to optimize the product's risk/benefit ratio, FDA's Antiviral Drugs Advisory Committee recommended
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy